365 related articles for article (PubMed ID: 19944069)
1. Protease and helicase activities of hepatitis C virus genotype 4, 5, and 6 NS3-NS4A proteins.
Massariol MJ; Zhao S; Marquis M; Thibeault D; White PW
Biochem Biophys Res Commun; 2010 Jan; 391(1):692-7. PubMed ID: 19944069
[TBL] [Abstract][Full Text] [Related]
2. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
López-Labrador FX; Moya A; Gonzàlez-Candelas F
Antivir Ther; 2008; 13(4):481-94. PubMed ID: 18672527
[TBL] [Abstract][Full Text] [Related]
3. Use of the fused NS4A peptide-NS3 protease domain to study the importance of the helicase domain for protease inhibitor binding to hepatitis C virus NS3-NS4A.
Thibeault D; Massariol MJ; Zhao S; Welchner E; Goudreau N; Gingras R; Llinàs-Brunet M; White PW
Biochemistry; 2009 Feb; 48(4):744-53. PubMed ID: 19119853
[TBL] [Abstract][Full Text] [Related]
4. Bismacrocyclic inhibitors of hepatitis C NS3/4a protease.
McCauley JA; Rudd MT; Nguyen KT; McIntyre CJ; Romano JJ; Bush KJ; Varga SL; Ross CW; Carroll SS; DiMuzio J; Stahlhut MW; Olsen DB; Lyle TA; Vacca JP; Liverton NJ
Angew Chem Int Ed Engl; 2008; 47(47):9104-7. PubMed ID: 18925594
[No Abstract] [Full Text] [Related]
5. A wide range of NS3/4A protease catalytic efficiencies in HCV-infected individuals.
Franco S; Clotet B; Martínez MA
Virus Res; 2008 Feb; 131(2):260-70. PubMed ID: 18037183
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and antiviral activity of HCV NS3/4A peptidomimetic boronic acid inhibitors.
Boloor A; Hanway D; Joshi M; Winn DT; Mendez G; Walls M; Wei P; Qian F; Zhang X; Zhang Y; Hepperle ME; Li X; Campbell DA; Betancort JM
Bioorg Med Chem Lett; 2009 Oct; 19(19):5708-11. PubMed ID: 19713109
[TBL] [Abstract][Full Text] [Related]
7. Mechanistic and kinetic characterization of hepatitis C virus NS3 protein interactions with NS4A and protease inhibitors.
Geitmann M; Dahl G; Danielson UH
J Mol Recognit; 2011; 24(1):60-70. PubMed ID: 21194118
[TBL] [Abstract][Full Text] [Related]
8. Structural characterization of the Hepatitis C Virus NS3 protease from genotype 3a: the basis of the genotype 1b vs. 3a inhibitor potency shift.
Gallo M; Bottomley MJ; Pennestri M; Eliseo T; Paci M; Koch U; Bazzo R; Summa V; Carfì A; Cicero DO
Virology; 2010 Sep; 405(2):424-38. PubMed ID: 20630554
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of BILN 2061, an HCV NS3 protease inhibitor with proven antiviral effect in humans.
Faucher AM; Bailey MD; Beaulieu PL; Brochu C; Duceppe JS; Ferland JM; Ghiro E; Gorys V; Halmos T; Kawai SH; Poirier M; Simoneau B; Tsantrizos YS; Llinàs-Brunet M
Org Lett; 2004 Aug; 6(17):2901-4. PubMed ID: 15330643
[TBL] [Abstract][Full Text] [Related]
10. Development of hepatitis C virus chimeric replicons for identifying broad spectrum NS3 protease inhibitors.
Binder J; Tetangco S; Weinshank M; Maegley K; Lingardo L; Diehl W; Love R; Patick AK; Smith GJ
Antiviral Res; 2011 Aug; 91(2):102-11. PubMed ID: 21620899
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C virus NS3 RNA helicase activity is modulated by the two domains of NS3 and NS4A.
Kuang WF; Lin YC; Jean F; Huang YW; Tai CL; Chen DS; Chen PJ; Hwang LH
Biochem Biophys Res Commun; 2004 Apr; 317(1):211-7. PubMed ID: 15047170
[TBL] [Abstract][Full Text] [Related]
12. The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic.
Tsantrizos YS
Biopolymers; 2004; 76(4):309-23. PubMed ID: 15386268
[TBL] [Abstract][Full Text] [Related]
13. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.
Lamarre D; Anderson PC; Bailey M; Beaulieu P; Bolger G; Bonneau P; Bös M; Cameron DR; Cartier M; Cordingley MG; Faucher AM; Goudreau N; Kawai SH; Kukolj G; Lagacé L; LaPlante SR; Narjes H; Poupart MA; Rancourt J; Sentjens RE; St George R; Simoneau B; Steinmann G; Thibeault D; Tsantrizos YS; Weldon SM; Yong CL; Llinàs-Brunet M
Nature; 2003 Nov; 426(6963):186-9. PubMed ID: 14578911
[TBL] [Abstract][Full Text] [Related]
14. Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061.
Thibeault D; Bousquet C; Gingras R; Lagacé L; Maurice R; White PW; Lamarre D
J Virol; 2004 Jul; 78(14):7352-9. PubMed ID: 15220408
[TBL] [Abstract][Full Text] [Related]
15. Development of robust in vitro serine protease assay based on recombinant Pakistani HCV NS3-4A protease.
Fatima K; Tahir M; Qadri I
Virus Res; 2011 Sep; 160(1-2):230-7. PubMed ID: 21756947
[TBL] [Abstract][Full Text] [Related]
16. High-throughput cell-based screening for hepatitis C virus NS3/4A protease inhibitors.
Lee JC; Yu MC; Lien TW; Chang CF; Hsu JT
Assay Drug Dev Technol; 2005 Aug; 3(4):385-92. PubMed ID: 16180993
[TBL] [Abstract][Full Text] [Related]
17. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C.
Reiser M; Hinrichsen H; Benhamou Y; Reesink HW; Wedemeyer H; Avendano C; Riba N; Yong CL; Nehmiz G; Steinmann GG
Hepatology; 2005 Apr; 41(4):832-5. PubMed ID: 15732092
[TBL] [Abstract][Full Text] [Related]
18. A novel recombinant single-chain hepatitis C virus NS3-NS4A protein with improved helicase activity.
Howe AY; Chase R; Taremi SS; Risano C; Beyer B; Malcolm B; Lau JY
Protein Sci; 1999 Jun; 8(6):1332-41. PubMed ID: 10386883
[TBL] [Abstract][Full Text] [Related]
19. Resistance of hepatitis C virus to NS3-4A protease inhibitors: mechanisms of drug resistance induced by R155Q, A156T, D168A and D168V mutations.
Courcambeck J; Bouzidi M; Perbost R; Jouirou B; Amrani N; Cacoub P; Pèpe G; Sabatier JM; Halfon P
Antivir Ther; 2006; 11(7):847-55. PubMed ID: 17302247
[TBL] [Abstract][Full Text] [Related]
20. Development of a cell-based assay for monitoring hepatitis C virus ns3/4a protease activity.
Lei YF; Yin W; Yang J; Lv X; Wei SH; An QX; Hu XB; Xu ZK
Acta Virol; 2008; 52(3):133-41. PubMed ID: 18999887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
